U.S., Oct. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07907783) titled 'Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia' on Oct. 24.
Brief Summary: The study is designed to evaluate safety and efficacy of PP405 in adult female participants with androgenetic alopecia
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Androgenetic Alopecia
Intervention:
DRUG: PP405 0.05% Topical Gel
Medicated topical gel containing PP405 0.05%
DRUG: Vehicle Topical Gel
Topical gel
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Pelage Pharmaceuticals, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....